antipsychotics Flashcards
What is the indication for clozapine?
recurrent suicidal behavior
multi-drug resistant disease
What is the indication for pimavanserin?
hallucinations/delusions associated with parkinson disease psychosis
Positive symptoms of schizophrenia are related to what pathway
overactivity of the mesolimbic pathway
Negative symptoms of schizophrenia are related to what pathway
mesocortical pathway dysfunction
What are the positive symptoms of schizophrenia
hallucinations, delusions, disorganized speech/thinking, agitation, abnormal motor behavior
What are the negative symptoms of schizophrenia
apathy, avolition (decreased motivation), alogia (complete lack of speech), cognitive deficits, social withdrawal
Nigrostriatal pathway
projections from substantia nigra to basal ganglia
- -stimulation of purposeful movement
- -D2 antagonism induces extrapyramidal symptoms (pseudoparkinsonism & tardive dyskinsea)
Tuberoinfundibular pathway
projections from hypothalamus to infundibular region
- -dopamine is released & tonically inhibits prolactin release
- -D2 antagonism increases prolactin levels
How long must therapy be before evaluating for response
2-3 weeks
remission may take several months
First generation antipsychotics block what
dopamine type-2 post synaptic receptors
also, block muscarinics, histaminics, alphas, D2s in nigrostriatal & tuberoinfundibular pathways
1st gen SEs
dry mouth, constipation, urinary retention, blurred vision
ortho hypotension, dizziness/syncope
sedation
risk of QTc prolongation & seizure activity
hyperprolactinemia
extrapyrimidal symptoms (movement)
Which are the 1st gen low potency agents
chlopromazine
thioridazine
more sedation, hypotension, & seizure-threshold reducation
Which are the 1st gen high potency agents
fluphenazine
haloperidol
more movement & endocrine effects
What are the treatments for the extrapyramidal symptoms
- anticholinergic agents: benztropine & trihexyphenidyl
2. antihistamine agents: diphenhydramine
What are the treatments for tardive dyskinesia
- selective vesicular monoamine transporter 2 inhibitors: valbenazine & deutetrabenazine